& Sherwood Investigates OvaScience, Inc. for Possible Breaches of Fiduciary
City, OK (June
10, 2014) – The law firm of Federman & Sherwood has initiated
an investigation into OvaScience, Inc. [NASDAQ: OVAS] with respect to alleged
violations of the federal securities laws.
September 10, 2013, the Company disclosed that it was suspending enrollment of
the AUGMENT clinical trial in the United States after the Company received an
untitled letter from the FDA questioning whether AUGMENT qualified for reduced
regulatory oversight and advising the Company to file an Investigational New
Drug application. Following this news, the Company’s shares dropped 23%, or
$3.325 per share, to close at $10.95 per share on September 11, 2013.
you currently own common stock in OvaScience, Inc., have any information to assist
in our investigation, or have questions or concerns regarding this notice or
your rights or interests in this matter, please contact Federman &
Sherwood, or complete the attached investor certification to be added to our
database for this company. Federman & Sherwood has extensive nationwide
experience in representing investors in securities, derivative and
merger-related shareholder class actions, and has been appointed as lead
counsel in multiple complex cases across the country.
Posted on Tue, June 10, 2014
by K. Lynn Nunn filed under